BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11872380)

  • 1. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
    Rosak C
    J Diabetes Complications; 2002; 16(1):123-32. PubMed ID: 11872380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride.
    Korytkowski MT
    Pharmacotherapy; 2004 May; 24(5):606-20. PubMed ID: 15162895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral antidiabetic drugs: an overview.
    Melander A
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S143-7. PubMed ID: 8894498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of type 2 diabetes mellitus: pharmacologic intervention.
    McCormick M; Quinn L
    J Cardiovasc Nurs; 2002 Jan; 16(2):55-67. PubMed ID: 11800068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of current therapeutic interventions on insulin resistance.
    Kobayashi M
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S32-40. PubMed ID: 11220286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.
    Hu S; Wang S; Dunning BE
    Int J Exp Diabetes Res; 2001; 2(1):63-72. PubMed ID: 12369728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.
    Raptis SA; Dimitriadis GD
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S265-87. PubMed ID: 11460577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Repaglinide in combination therapy in type 2 diabetes].
    Moses R
    Diabetes Metab; 1999 Dec; 25 Suppl 7():26-7. PubMed ID: 10746009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.
    Brown DL; Brillon D
    J Natl Med Assoc; 1999 Jul; 91(7):389-95. PubMed ID: 10643211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.
    Harrigan RA; Nathan MS; Beattie P
    Ann Emerg Med; 2001 Jul; 38(1):68-78. PubMed ID: 11423816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy of type 2 diabetes mellitus.
    Rendell MS; Kirchain WR
    Ann Pharmacother; 2000; 34(7-8):878-95. PubMed ID: 10928401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Present status in the treatment of type 2 diabetes mellitus. Insulin-secreting agents].
    Blicklé JF; Andres E; Neyrolles N; Brogard JM
    Rev Med Interne; 1999 Aug; 20 Suppl 3():351s-359s. PubMed ID: 10480186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
    Lebovitz HE
    Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug treatment of type 2 diabetes].
    Tielmans A; Laloi-Michelin M; Coupaye M; Virally M; Meas T; Guillausseau PJ
    Presse Med; 2007 Feb; 36(2 Pt 2):269-78. PubMed ID: 17258675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
    Kitaoka H
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():464-9. PubMed ID: 12387035
    [No Abstract]   [Full Text] [Related]  

  • 19. Insulin secretagogues.
    Davies MJ
    Curr Med Res Opin; 2002; 18 Suppl 1():s22-30. PubMed ID: 12365816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies.
    Giorgino F; Laviola L; Leonardini A
    Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S22-9. PubMed ID: 15955371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.